These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34265496)

  • 21. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
    Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
    Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson L; Lawrence D; Dawson C; Bliss J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S; Verma S
    Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea.
    Kim JE; Choi J; Park J; Han W; Kang D; Choi JY
    J Am Heart Assoc; 2022 Oct; 11(20):e026743. PubMed ID: 36250658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
    Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
    Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
    Seruga B; Zadnik V; Kuhar CG; Marinko T; Cufer T; Zakotnik B; Zorman D; Ocana A; Amir E
    Cancer Invest; 2014 May; 32(4):99-104. PubMed ID: 24548302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis.
    Yoo JJ; Jung EA; Kim Z; Kim BY
    Curr Oncol; 2023 Feb; 30(2):1831-1843. PubMed ID: 36826103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
    Ewer MS; Glück S
    Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Siesling S; Hauptmann M; Linn SC
    J Natl Cancer Inst; 2021 Nov; 113(11):1506-1514. PubMed ID: 34101806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
    Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
    J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
    Carlini P; Bria E; Giannarelli D; Felici A; Papaldo P; Fabi A; Ruggeri EM; Milella M; Nuzzo C; Cecere FL; Gelibter A; Pino MS; Nisticò C; Cuppone F; Metro G; Terzoli E; Cognetti F; Ferretti G
    Expert Opin Investig Drugs; 2007 Jul; 16(7):1023-36. PubMed ID: 17594187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.